Insider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Director Sells 20,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Julian S. Gangolli sold 20,000 shares of the business's stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Krystal Biotech Stock Up 1.5 %

KRYS traded up $2.42 on Wednesday, hitting $169.25. 338,825 shares of the company traded hands, compared to its average volume of 347,666. Krystal Biotech, Inc. has a 12-month low of $93.95 and a 12-month high of $189.97. The company has a 50 day moving average of $167.30 and a 200-day moving average of $137.19. The stock has a market capitalization of $4.83 billion, a PE ratio of 90.51 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million during the quarter, compared to analyst estimates of $47.37 million. During the same period in the prior year, the company earned ($1.76) earnings per share. Krystal Biotech's revenue for the quarter was up 452400.0% on a year-over-year basis. On average, research analysts anticipate that Krystal Biotech, Inc. will post 2.06 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on KRYS shares. William Blair restated an "outperform" rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Citigroup upped their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a "buy" rating in a report on Tuesday, February 27th. Guggenheim lifted their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday, February 27th. Stifel Nicolaus reissued a "buy" rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $200.00 price target on shares of Krystal Biotech in a research report on Monday, May 6th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and a consensus price target of $177.63.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quest Partners LLC acquired a new position in shares of Krystal Biotech in the fourth quarter worth $127,000. Pier 88 Investment Partners LLC acquired a new position in Krystal Biotech in the 4th quarter valued at about $145,000. Fox Run Management L.L.C. purchased a new position in Krystal Biotech in the 3rd quarter valued at about $219,000. Caxton Associates LP acquired a new stake in shares of Krystal Biotech during the 1st quarter worth about $232,000. Finally, Lazard Asset Management LLC grew its holdings in shares of Krystal Biotech by 27.5% during the first quarter. Lazard Asset Management LLC now owns 1,308 shares of the company's stock worth $232,000 after buying an additional 282 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.